AK129 / Akesobio 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AK129 / Akesobio
NCT06586294: A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Not yet recruiting
1/2
294
RoW
Drug: AK129 Drug：oxaliplatin Drug：capecitabine, Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine
Akeso
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
07/26
07/26
NCT06642792: A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Not yet recruiting
1/2
280
RoW
AK129, AK117
Akeso
Classic Hodgkin Lymphoma
11/27
02/28
NCT05645276: A Study of AK129 in Patients With Advanced Malignant Tumors

Recruiting
1a/1b
182
RoW
AK129 IV infusion
Akeso
Advanced Malignant Tumors(Stage IA-IB)
02/25
02/25

Download Options